Runben Biotechnology Co

Runben Biotechnology Co Equity

The The Equity of Runben Biotechnology Co (603193.SS) as of Oct 15, 2026 is 2.22 B CNY. In the previous year, The Equity was 2.08 B CNY — a change of 6.75% (higher).

Equity

2.22 BCNY

YoY

6.75%

Last updated:

In 2025, Runben Biotechnology Co's equity was 2.22 B CNY, a 6.75% increase from the 2.08 B CNY equity in the previous year.

The Runben Biotechnology Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
137.36 M CNY
Jan 1, 2020
250.14 M CNY
Jan 1, 2021
561.65 M CNY
Jan 1, 2022
722.59 M CNY
Jan 1, 2023
1.92 B CNY
Jan 1, 2024
2.08 B CNY
Jan 1, 2025
2.22 B CNY
The Runben Biotechnology Co Equity history
YEAREquityYoY
2.22 BCNY+6.75%
2.08 BCNY+8.29%
1.92 BCNY+165.89%
722.59 MCNY+28.66%
561.65 MCNY+124.53%
250.14 MCNY+82.10%
137.36 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Runben Biotechnology Co Stock analysis

What does Runben Biotechnology Co do? Runben Biotechnology Co Ltd, trading under the ticker symbol 603193.SS and identified by ISIN CNE100006DK5, is a Chinese enterprise operating within the Consumer Staples sector, specifically in the consumer products industry. Headquartered in Guangzhou, Guangdong, the company has established itself as a specialized manufacturer and distributor of personal care items, with a notable focus on mosquito repellents and baby care solutions. As of the latest available data, the firm employs 917 full-time staff members who support its extensive research, development, manufacturing, and sales operations. Runben Biotechnology officially entered the public markets via an initial public offering on October 17, 2023, marking a significant milestone in its corporate development and providing greater visibility into its financial and operational strategies. The company’s product portfolio is strategically divided into three primary categories: mosquito repellent products, baby care products, and essential oil-based items. Among its best-selling offerings are electric mosquito repellent liquids and DEET-based repellent solutions, which cater to the growing consumer demand for effective and safe pest control measures. In the personal care segment, the firm produces a diverse range of skincare and hygiene products, including lipsticks, face creams, facial cleansers, and general skincare creams, targeting consumers who prioritize gentle and specialized formulations. The company’s business model relies heavily on digital commerce channels, utilizing internet sales platforms to reach its customer base directly. This includes online direct sales, distribution through major online platforms, and agency sales models that facilitate broader market penetration. By leveraging these e-commerce strategies, Runben Biotechnology has been able to maintain a strong presence in the domestic Chinese market, where the majority of its revenue is generated. The firm’s commitment to innovation in product formulation, combined with its agile distribution network, positions it as a competitive player in the crowded consumer goods landscape. Through its continued investment in research and development, the company aims to expand its product lines and enhance the quality of its offerings, ensuring it meets the evolving needs of modern consumers. The integration of traditional manufacturing expertise with modern digital sales tactics allows Runben Biotechnology to adapt quickly to market trends and maintain customer loyalty. As it continues to grow, the company remains focused on delivering high-quality, safe, and effective products that address everyday consumer concerns, particularly in the areas of personal hygiene and family care. Runben Biotechnology Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Runben Biotechnology Co's Equity

Runben Biotechnology Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Runben Biotechnology Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Runben Biotechnology Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Runben Biotechnology Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Runben Biotechnology Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Runben Biotechnology Co stock

The Equity of Runben Biotechnology Co is 2.22 B CNY in 2025.

The Equity of Runben Biotechnology Co changed from 2.08 B CNY to 2.22 B CNY, representing a 6.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Runben Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Runben Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Runben Biotechnology Co

All Key Metrics — Runben Biotechnology Co